Insulet Beats Q3 EPS Estimates, Attracts $16.7M Institutional Buy and $415 Price Target
Insulet reported Q3 EPS of $1.24 beating estimates by $0.11 while revenue rose 29.9% y/y to $521.7M, narrowly missing the $678.7M consensus. The company attracted new institutional investment with Braun Stacey Associates acquiring $16.7M in stock and analysts raising price targets up to $415.
1. Institutional Buying Signals Growing Confidence
In the third quarter, Braun Stacey Associates acquired 53,952 shares of Insulet, representing a $16.7 million commitment and bringing its stake to 0.08% of the company. During the second quarter, Vanguard Group increased its position by 39,403 shares to 8.71 million shares, Geode Capital added 58,309 shares to reach 1.93 million shares, Federated Hermes bought 90,494 shares boosting its holding to 723,363 shares, and Charles Schwab Investment Management added 6,763 shares to reach 681,130 shares. Norges Bank also initiated a new position valued at $324.7 million. These moves underscore growing institutional conviction in Insulet’s growth trajectory and market positioning.
2. Accelerating Revenue and Margin Expansion
In its latest quarter, Insulet reported revenue of $521.7 million, up 29.9% year-over-year, driven by strong adoption of its Omnipod 5 system. The company delivered $1.24 in earnings per share, surpassing consensus by $0.11. Net margin reached 9.76% and return on equity stood at 24.36%. Management noted that pod volume increased more than 40% year-over-year, helping operating margins expand by 250 basis points sequentially as manufacturing efficiencies scaled.
3. Upward Revision of Earnings Estimates
Equity analysts have lifted full-year EPS forecasts to an average of 3.92, reflecting faster-than-expected uptake of the tubeless insulin pump and improving gross margins. Consensus revenue projections have been revised to $2.1 billion, up from $1.9 billion at the start of the year. Insulet’s guidance for pod unit growth of 35%–40% and margin expansion of 300–350 basis points has bolstered estimates for both operating income and free cash flow generation.
4. Strong Analyst Ratings and Price Targets
Among 25 analysts covering Insulet, one rates the stock as Strong Buy, 22 as Buy and two as Hold, for an average rating of Moderate Buy. Price targets have been increased across the board: Raymond James lifted its target to $385, Wolfe Research to $375, Rothschild & Co Redburn to $370, Leerink Partners to $386 and JPMorgan Chase to $415. This consensus reflects confidence in Insulet’s product pipeline, reimbursement environment and ongoing margin leverage.